Since p21 accumulation is a part of the mechanism of action for both proteasome inhibitors [14] and immunomodulatory agents [19], [27], these findings together support the possibility that approaches targeting MDM2 could be attractive options for myeloma patients. Here, MDM2 is linked to plasma cell myeloma.